In the Claims:

Please amend the claims as shown:

1. (currently amended) A peptide having a sequence comprising or consisting of QPLALEGSLQK **(SEQ ID NO: 9)**.

2. (currently amended) A peptide selected from the group consisting of GGGPGAGSLQPLALEGSLQK **(SEQ ID NO: 4)**, GSLQPLALEGSLQKRGIV **(SEQ ID NO: 5)**, and QPLALEGSLQKRGIVEQ **(SEQ ID NO: 6).**

3. (currently amended) The peptide having the sequence GSLQPLALEGSLQKRGIV **(SEQ ID NO: 5)**.

4. (currently amended) The peptide having the sequence GGGPGAGSLQPLALEGSLQKRGIVEQ **(SEQ ID NO: 10).**

5. (currently amended) A peptide according to any of claims 1 to 4, in combination with one or more peptides having a sequence selected from LAKEWQALCAYQAEPNTCATAQGEGNIK **(SEQ ID NO: 11)**, KLKVESSPSRSDYINASPIIEHDP **(SEQ ID NO: 12)**, and SFYLKNVQTQETRTLTQFHF **(SEQ ID NO: 13)**.

6. (original) A peptide or peptide combination according to any of the preceding claims, comprising a peptide or peptides differing from those specified by up to and including 4 amino acid alterations (substitution and/or deletion and/or insertion) or one which is extended from any one of the above-mentioned residues at the N-terminus or C-terminus or both with one or more non-wild-type amino acid sequences.

7. (original) A peptide according to any of claims 1-6 in combination with either
    a. IA-2 752-75
    b. IA-2 853-72
    c. IA-2 709-36
    d. IA-2 752-75 and IA-2 853-72
    e. IA-2 709-36 and IA-2 752-75

f. IA-2 709-36 and IA-2 853-72, or

g. IA-2 709-36 and IA-2 752-75 and IA-2 853-72

8. (original) A pharmaceutical composition comprising a peptide or peptide combination according to any of claims 1 to 7, for the therapy of Type 1 diabetes.

9. (original) A pharmaceutical composition according to claim 8, in which the peptide or each peptide is conjugated or otherwise combined with a tolerance-promoting adjuvant or tolerance promoting cells.

10. (original)A diagnostic method or kit for diagnosis of, or determination of a predisposition to, Type 1 diabetes, comprising a peptide or peptide combination according to any of the preceding claims.

11. (original) A method of treatment or prevention of Type 1 diabetes, in which a peptide or combination of peptides according to any of claims 1 to 7 is administered by parenteral or oral or topical routes, including intradermal, subcutaneous or intravenous injection, or nasally or orally or epicutaneously..

12. (original) A method according to claim 11, in which the peptide or each peptide in a combination of peptides is administered in an amount of up to about 1mg or more per single dose.

13. (original) A method according to claim 12, in which the peptide or each peptide in a combination of peptides is administered in an amount of from about 0.5 to about 500 micrograms or more per single dose.

14. (original) A method according to claim 13, in which a single dose contains from 5 to 250
μg of the, or each, peptide e.g. 5, 50, or 250 μg.

15. (original) A method according to any of claims 10 to 14, in which the peptide or combination is administered in conjunction with a tolerance-promoting adjuvant or tolerance promoting cells.